EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
This space already includes two approved therapies: Johnson & Johnson/Legend’s Carvykti and Bristol Myers Squibb’s Abecma.
Themes
Implementing pragmatic approaches for the patients and sites in oncology trials
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
Patient-centric approaches thrive on wearables and remote access in trials
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
Navigating the FDA’s accelerated approval pathways for oncology drugs
Pharma’s AI prospects get nudged into the future with EU’s AI act
Are regulators keeping pace with AI adoption in clinical trials?
